A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics
<p>Abstract</p> <p>Background</p> <p>PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.</p> <p>Methods</p...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2002-05-01
|
| Series: | Current Controlled Trials in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | http://cvm.controlled-trials.com/content/3/1/8 |
| _version_ | 1811250190245429248 |
|---|---|
| author | Lagaay A Margot Gaw Allan Hyland Michael Jukema J Wouter Buckley Brendan M Bollen Edward LEM Cobbe Stuart M Shepherd James Murphy Michael B Blauw Gerard Ford Ian Perry Ivan J Macfarlane Peter Norrie John Meinders A Edo Sweeney Brian J Packard Chris J Westendorp Rudi GJ Twomey Cillian Stott David J |
| author_facet | Lagaay A Margot Gaw Allan Hyland Michael Jukema J Wouter Buckley Brendan M Bollen Edward LEM Cobbe Stuart M Shepherd James Murphy Michael B Blauw Gerard Ford Ian Perry Ivan J Macfarlane Peter Norrie John Meinders A Edo Sweeney Brian J Packard Chris J Westendorp Rudi GJ Twomey Cillian Stott David J |
| author_sort | Lagaay A Margot |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.</p> <p>Methods</p> <p>The <b>PRO</b>spective <b>S</b>tudy of <b>P</b>ravastatin in the <b>E</b>lderly at <b>R</b>isk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition.</p> <p>Results</p> <p>In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0–9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women).</p> <p>Conclusions</p> <p>Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.</p> |
| first_indexed | 2024-04-12T16:00:43Z |
| format | Article |
| id | doaj.art-a5c6e299ce254e5da942c65e57046d71 |
| institution | Directory Open Access Journal |
| issn | 1468-6708 |
| language | English |
| last_indexed | 2024-04-12T16:00:43Z |
| publishDate | 2002-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Current Controlled Trials in Cardiovascular Medicine |
| spelling | doaj.art-a5c6e299ce254e5da942c65e57046d712022-12-22T03:26:13ZengBMCCurrent Controlled Trials in Cardiovascular Medicine1468-67082002-05-0131810.1186/1468-6708-3-8A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsLagaay A MargotGaw AllanHyland MichaelJukema J WouterBuckley Brendan MBollen Edward LEMCobbe Stuart MShepherd JamesMurphy Michael BBlauw GerardFord IanPerry Ivan JMacfarlane PeterNorrie JohnMeinders A EdoSweeney Brian JPackard Chris JWestendorp Rudi GJTwomey CillianStott David J<p>Abstract</p> <p>Background</p> <p>PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.</p> <p>Methods</p> <p>The <b>PRO</b>spective <b>S</b>tudy of <b>P</b>ravastatin in the <b>E</b>lderly at <b>R</b>isk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition.</p> <p>Results</p> <p>In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0–9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women).</p> <p>Conclusions</p> <p>Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.</p>http://cvm.controlled-trials.com/content/3/1/8clinical trialelderlypravastatinbaseline characteristics |
| spellingShingle | Lagaay A Margot Gaw Allan Hyland Michael Jukema J Wouter Buckley Brendan M Bollen Edward LEM Cobbe Stuart M Shepherd James Murphy Michael B Blauw Gerard Ford Ian Perry Ivan J Macfarlane Peter Norrie John Meinders A Edo Sweeney Brian J Packard Chris J Westendorp Rudi GJ Twomey Cillian Stott David J A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics Current Controlled Trials in Cardiovascular Medicine clinical trial elderly pravastatin baseline characteristics |
| title | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics |
| title_full | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics |
| title_fullStr | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics |
| title_full_unstemmed | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics |
| title_short | A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics |
| title_sort | prospective study of pravastatin in the elderly at risk prosper screening experience and baseline characteristics |
| topic | clinical trial elderly pravastatin baseline characteristics |
| url | http://cvm.controlled-trials.com/content/3/1/8 |
| work_keys_str_mv | AT lagaayamargot aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT gawallan aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT hylandmichael aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT jukemajwouter aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT buckleybrendanm aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT bollenedwardlem aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT cobbestuartm aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT shepherdjames aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT murphymichaelb aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT blauwgerard aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT fordian aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT perryivanj aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT macfarlanepeter aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT norriejohn aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT meindersaedo aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT sweeneybrianj aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT packardchrisj aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT westendorprudigj aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT twomeycillian aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT stottdavidj aprospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT lagaayamargot prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT gawallan prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT hylandmichael prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT jukemajwouter prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT buckleybrendanm prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT bollenedwardlem prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT cobbestuartm prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT shepherdjames prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT murphymichaelb prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT blauwgerard prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT fordian prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT perryivanj prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT macfarlanepeter prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT norriejohn prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT meindersaedo prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT sweeneybrianj prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT packardchrisj prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT westendorprudigj prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT twomeycillian prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics AT stottdavidj prospectivestudyofpravastatinintheelderlyatriskprosperscreeningexperienceandbaselinecharacteristics |